Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals has $34.0 highest and $20.0 lowest target. $27.33’s average target is 35.63% above currents $20.15 stock price. Concert Pharmaceuticals had 20 analyst reports since August 12, 2015 according to SRatingsIntel. Roth Capital maintained the shares of CNCE in report on Tuesday, September 22 with “Buy” rating. The firm earned “Buy” rating on Monday, November 6 by Mizuho. UBS maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, December 19 with “Buy” rating. On Friday, November 10 the stock rating was maintained by H.C. Wainwright with “Buy”. Brean Capital initiated Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rating on Wednesday, August 12. Brean Capital has “Buy” rating and $21 target. As per Monday, September 18, the company rating was maintained by H.C. Wainwright. The company was maintained on Monday, June 12 by Aegis Capital. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9. H.C. Wainwright maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rating on Friday, October 20. H.C. Wainwright has “Buy” rating and $21.0 target. The rating was maintained by Aegis Capital with “Buy” on Thursday, June 29.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. The company has market cap of $18.74 billion. The Company’s programmable devices comprise integrated circuits in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; software development environments and embedded platforms; targeted reference designs; printed circuit boards; and intellectual property (IP). It has a 31.4 P/E ratio. The firm also offers development boards; development kits, including hardware, design tools, IP, and reference creates that are designed to streamline and accelerate the development of domain-specific and market-specific applications; and configuration products, such as one-time programmable and in-system programmable storage devices to configure field programmable gate arrays.
Analysts await Xilinx, Inc. (NASDAQ:XLNX) to report earnings on January, 24. They expect $0.63 EPS, up 21.15% or $0.11 from last year’s $0.52 per share. XLNX’s profit will be $158.10 million for 29.63 P/E if the $0.63 EPS becomes a reality. After $0.65 actual EPS reported by Xilinx, Inc. for the previous quarter, Wall Street now forecasts -3.08% negative EPS growth.
Since January 1, 0001, it had 0 insider purchases, and 5 insider sales for $15.35 million activity.
Blue Harbour Group L.P. holds 11.7% of its portfolio in Xilinx, Inc. for 4.58 million shares. Tahithromos L.L.C. owns 91,797 shares or 7.86% of their US portfolio. Moreover, Sadoff Investment Management Llc has 4.24% invested in the company for 670,025 shares. The Connecticut-based Discovery Capital Management Llc Ct has invested 4.12% in the stock. Ashmore Wealth Management Llc, a Delaware-based fund reported 932,367 shares.
The stock increased 0.43% or $0.32 during the last trading session, reaching $74.66. About 1.06 million shares traded. Xilinx, Inc. (XLNX) has risen 52.08% since January 13, 2017 and is uptrending. It has outperformed by 35.38% the S&P500.
Ratings analysis reveals 33% of Xilinx’s analysts are positive. Out of 3 Wall Street analysts rating Xilinx, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $48.0 while the high is $52.0. The stock’s average target of $50 is -33.03% below today’s ($74.66) share price. XLNX was included in 3 notes of analysts from October 12, 2016. The firm has “Overweight” rating by Morgan Stanley given on Thursday, December 15. The stock has “Equal Weight” rating by Barclays Capital on Thursday, October 20. The stock of Xilinx, Inc. (NASDAQ:XLNX) has “Neutral” rating given on Wednesday, October 12 by Robert W. Baird.
Since September 14, 2017, it had 1 insider buy, and 1 insider sale for $5.21 million activity. 331,916 shares valued at $5.26M were bought by BVF PARTNERS L P/IL on Thursday, October 19. Lynch Ryan sold $50,785 worth of stock or 3,500 shares.
The stock decreased 27.20% or $7.53 during the last trading session, reaching $20.15. About 3.41M shares traded or 702.80% up from the average. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 18.70% since January 13, 2017 and is uptrending. It has outperformed by 2.00% the S&P500.
Investors sentiment increased to 1.18 in Q3 2017. Its up 0.05, from 1.13 in 2017Q2. It increased, as 13 investors sold Concert Pharmaceuticals, Inc. shares while 20 reduced holdings. 17 funds opened positions while 22 raised stakes. 14.57 million shares or 5.31% more from 13.83 million shares in 2017Q2 were reported. First Manhattan Communications has 68,900 shares. Rockefeller Fin Svcs stated it has 9,533 shares. Nationwide Fund Advsr invested in 9,861 shares or 0% of the stock. Alliancebernstein Ltd Partnership invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Legal General Gp Plc invested in 5,414 shares. Franklin Resources holds 687,000 shares or 0% of its portfolio. 1,187 are owned by Ameritas Inv Prtnrs Inc. American International Gru Incorporated reported 0% stake. State Of Wisconsin Invest Board has invested 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Plante Moran Fincl Advsrs Limited Liability Company has 0.01% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Point72 Asset Mgmt L P holds 57,134 shares or 0% of its portfolio. Renaissance Limited Liability Corp stated it has 379,900 shares or 0.01% of all its holdings. Knott David M stated it has 45,000 shares or 0.28% of all its holdings. Manchester Cap Management Ltd Liability, a Vermont-based fund reported 19,984 shares. Blackrock has invested 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $458.87 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 5.19 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.